In a mouse model of diet-induced obesity, the chronic exogenous administration of KYNA halts body weight gain and reduces adiposity in the subcutaneous WAT through the activation at GPR35, which increases the expression of gene networks involved in thermogenesis through the process of browning, lipid metabolism, and type 2 anti-inflammatory immune responses. The gene discussed is GPR35; the disease is obesity disorder.